Korean J Gastroenterol.  2017 Feb;69(2):93-95. 10.4166/kjg.2017.69.2.93.

Do We Need to Change the Treatment Strategy for Spontaneous Bacterial Peritonitis in Patients with Advanced Cirrhosis?

• Kim CW

• KMID: 2383417
• DOI: http://doi.org/10.4166/kjg.2017.69.2.93

Abstract

No abstract available.

MeSH Terms

Fibrosis*
Humans
Peritonitis*

Reference

References

1. Moreau R, Arroyo V. Acute-on-chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2015; 13:836–841.

2. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology. 1991; 100:1737–1742.

3. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341:403–409.

4. Guarner C, Sola R, Soriano G, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology. 1999; 117:414–419.

5. Lee JM, Han KH, Ahn SH. Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol. 2009; 24:1494–1503.

6. Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012; 18:1–21.

7. Park MK, Lee JH, Byun YH, et al. Changes in the profiles of causative agents and antibiotic resistance rate for spontaneous bacterial peritonitis: an analysis of cultured microorganisms in recent 12 years. Korean J Hepatol. 2007; 13:370–377.

8. Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram-positive cocci and gram-negative multi-drug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int. 2013; 33:975–981.

9. Hagen EA, Lautenbach E, Olthoff K, Blumberg EA. Low prevalence of colonization with vancomycin-resistant Enterococcus in patients awaiting liver transplantation. Am J Transplant. 2003; 3:902–905.

10. Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc. 2015; 90:395–403.

11. Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012; 55:1551–1561.

12. Ariza X, Castellote J, Lora-Tamayo J, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol. 2012; 56:825–832.

13. Runyon BA. Changing flora of bacterial infections in patients with cirrhosis. Liver Int. 2010; 30:1245–1246.

14. Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49:2087–2107.

15. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53:397–417.

16. Na HY, Kim JH, Choe WH, Kwon SY, Yoo B. Clinical features of spontaneous bacterial peritonitis: a 10-year experience from a single center. Korean J Gastroenterol. 2017; 69:129–134.